Design Therapeutics, Inc. (DSGN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -79.36M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 58.78M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-79.36M | $0.00 | (m) | $58.78M | (m) | (m) |
| 2026-03-31 | $-78.75M | $0.00 | (m) | $58.13M | (m) | (m) |
| 2025-12-31 | $-79.47M | $0.00 | (m) | $59.13M | (m) | (m) |
| 2025-09-30 | $-77.99M | (m) | (m) | $57.86M | (m) | (m) |
| 2025-06-30 | $-74.93M | (m) | (m) | $55.15M | (m) | (m) |
| 2025-03-31 | $-68.40M | (m) | (m) | $49.93M | (m) | (m) |
| 2024-12-31 | $-62.38M | $0.00 | (m) | $44.35M | (m) | (m) |
| 2024-09-30 | $-60.81M | (m) | (m) | $43.20M | (m) | (m) |
| 2024-06-30 | $-63.39M | (m) | (m) | $44.59M | (m) | (m) |
| 2024-03-31 | $-70.94M | (m) | (m) | $51.13M | (m) | (m) |
| 2023-12-31 | $-78.19M | (m) | (m) | $57.06M | (m) | (m) |
| 2023-09-30 | $-82.46M | (m) | (m) | $60.31M | (m) | (m) |
| 2023-06-30 | $-82.83M | (m) | (m) | $61.35M | (m) | (m) |
| 2023-03-31 | $-75.87M | (m) | (m) | $55.58M | (m) | (m) |
| 2022-12-31 | $-67.59M | (m) | (m) | $48.61M | (m) | (m) |
| 2022-09-30 | $-59.33M | (m) | (m) | $41.70M | (m) | (m) |
| 2022-06-30 | $-51.47M | (m) | (m) | $35.93M | (m) | (m) |
| 2022-03-31 | $-43.52M | (m) | (m) | $29.66M | (m) | (m) |
| 2021-12-31 | $-35.83M | (m) | (m) | $24.78M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-8.33M | $226.00K | (m) | $6.06M | (m) | -3685.84% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |